Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen

Abstract Context The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 104; no. 6; pp. 1937 - 1947
Main Authors van Velzen, Daan M, Paldino, Alessia, Klaver, Maartje, Nota, Nienke M, Defreyne, Justine, Hovingh, G Kees, Thijs, Abel, Simsek, Suat, T’Sjoen, Guy, den Heijer, Martin
Format Journal Article
LanguageEnglish
Published Washington, DC Endocrine Society 01.06.2019
Copyright Oxford University Press
Oxford University Press
Subjects
Acetates
Acetic acid
Administration, Oral
Adolescent
Adult
Blood pressure
Blood Pressure - drug effects
Cardiovascular diseases
Cardiovascular Diseases - blood
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - prevention & control
Cholesterol
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Cyproterone acetate
Cyproterone Acetate - administration & dosage
Cyproterone Acetate - adverse effects
Estrogen
Estrogens
Estrogens - administration & dosage
Estrogens - adverse effects
Female
High density lipoprotein
Hormone Replacement Therapy - adverse effects
Hormone Replacement Therapy - methods
Hormones
Humans
Low density lipoprotein
Low density lipoproteins
Male
Phenols
Prospective Studies
Sex Factors
Sex Reassignment Procedures - adverse effects
Sex Reassignment Procedures - methods
Testosterone
Testosterone - administration & dosage
Testosterone - adverse effects
Transdermal medication
Transdermal Patch
Transgender people
Transgender Persons
Triglycerides
Triglycerides - blood
Young Adult
Belgium
Netherlands
Online AccessGet full text

Cover

Abstract Abstract Context The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. Design and Methods In this prospective, observational substudy of the European Network for the Investigation of Gender Incongruence, measurements were performed before and after 12 months of HT in 242 transwomen and 188 transmen from 2010 to 2017. Results Mean values are reported. In transmen, HT increased diastolic BP (2.5%; 95% CI, 0.6 to 4.4) and levels of total cholesterol (TC; 4.1%; 95% CI, 1.5 to 6.6), low-density lipoprotein–cholesterol (LDL-C; 13.0%; 95% CI, 9.2 to 16.8), and triglycerides (36.9%; 95% CI, 29.8 to 44.1); high-density lipoprotein–cholesterol levels decreased (HDL-C; 10.8%; 95% CI, −14.0 to −7.6). In transwomen, HT slightly decreased BP (systolic BP, −2.6%, 95% CI, −4.2 to −1.0; diastolic BP, −2.2%, 95% CI, −4.0 to −0.4) and decreased levels of TC (−9.7%; 95% CI, −11.3 to −8.1), LDL-C (−6.0%; 95% CI, −8.6 to 3.6), HDL-C (−9.3%; 95% CI, −11.4 to −7.3), and triglycerides (−10.2%; 95% CI, −14.5 to −5.9). Conclusion Unfavorable changes in lipid profile were observed in transmen; a favorable effect was noted in transwomen. HT effects on BP were negligible. Long-term studies are warranted to assess whether and to what extent HT in trans individuals results in a differential effect on cardiovascular disease outcomes. In this prospective observational study, favorable lipid changes were found in transwomen and unfavorable lipid changes found in transmen after 12 months of gender-affirming hormone therapy.
AbstractList The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. In this prospective, observational substudy of the European Network for the Investigation of Gender Incongruence, measurements were performed before and after 12 months of HT in 242 transwomen and 188 transmen from 2010 to 2017. Mean values are reported. In transmen, HT increased diastolic BP (2.5%; 95% CI, 0.6 to 4.4) and levels of total cholesterol (TC; 4.1%; 95% CI, 1.5 to 6.6), low-density lipoprotein-cholesterol (LDL-C; 13.0%; 95% CI, 9.2 to 16.8), and triglycerides (36.9%; 95% CI, 29.8 to 44.1); high-density lipoprotein-cholesterol levels decreased (HDL-C; 10.8%; 95% CI, -14.0 to -7.6). In transwomen, HT slightly decreased BP (systolic BP, -2.6%, 95% CI, -4.2 to -1.0; diastolic BP, -2.2%, 95% CI, -4.0 to -0.4) and decreased levels of TC (-9.7%; 95% CI, -11.3 to -8.1), LDL-C (-6.0%; 95% CI, -8.6 to 3.6), HDL-C (-9.3%; 95% CI, -11.4 to -7.3), and triglycerides (-10.2%; 95% CI, -14.5 to -5.9). Unfavorable changes in lipid profile were observed in transmen; a favorable effect was noted in transwomen. HT effects on BP were negligible. Long-term studies are warranted to assess whether and to what extent HT in trans individuals results in a differential effect on cardiovascular disease outcomes.
Context: The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective: The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. Design and Methods: In this prospective, observational substudy of the European Network for the Investigation of Gender Incongruence, measurements were performed before and after 12 months of HT in 242 transwomen and 188 transmen from 2010 to 2017. Results: Mean values are reported. In transmen, HT increased diastolic BP (2.5%; 95% CI, 0.6 to 4.4) and levels of total cholesterol (TC; 4.1%; 95% CI, 1.5 to 6.6), low-density lipoprotein-cholesterol (LDL-C; 13.0%; 95% CI, 9.2 to 16.8), and triglycerides (36.9%; 95% CI, 29.8 to 44.1); high-density lipoprotein-cholesterol levels decreased (HDL-C; 10.8%; 95% CI, -14.0 to -7.6). In transwomen, HT slightly decreased BP (systolic BP, -2.6%, 95% CI, -4.2 to -1.0; diastolic BP, -2.2%, 95% CI, -4.0 to -0.4) and decreased levels of TC (-9.7%; 95% CI, -11.3 to -8.1), LDL-C (-6.0%; 95% CI, -8.6 to 3.6), HDL-C (-9.3%; 95% CI, -11.4 to -7.3), and triglycerides (-10.2%; 95% CI, -14.5 to -5.9). Conclusion: Unfavorable changes in lipid profile were observed in transmen; a favorable effectwas noted in transwomen. HT effects on BP were negligible. Long-term studies are warranted to assess whether and to what extent HT in trans individuals results in a differential effect on cardiovascular disease outcomes. (J Clin Endocrinol Metab 104: 1937-1947, 2019)
CONTEXTThe impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. OBJECTIVEThe effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. DESIGN AND METHODSIn this prospective, observational substudy of the European Network for the Investigation of Gender Incongruence, measurements were performed before and after 12 months of HT in 242 transwomen and 188 transmen from 2010 to 2017. RESULTSMean values are reported. In transmen, HT increased diastolic BP (2.5%; 95% CI, 0.6 to 4.4) and levels of total cholesterol (TC; 4.1%; 95% CI, 1.5 to 6.6), low-density lipoprotein-cholesterol (LDL-C; 13.0%; 95% CI, 9.2 to 16.8), and triglycerides (36.9%; 95% CI, 29.8 to 44.1); high-density lipoprotein-cholesterol levels decreased (HDL-C; 10.8%; 95% CI, -14.0 to -7.6). In transwomen, HT slightly decreased BP (systolic BP, -2.6%, 95% CI, -4.2 to -1.0; diastolic BP, -2.2%, 95% CI, -4.0 to -0.4) and decreased levels of TC (-9.7%; 95% CI, -11.3 to -8.1), LDL-C (-6.0%; 95% CI, -8.6 to 3.6), HDL-C (-9.3%; 95% CI, -11.4 to -7.3), and triglycerides (-10.2%; 95% CI, -14.5 to -5.9). CONCLUSIONUnfavorable changes in lipid profile were observed in transmen; a favorable effect was noted in transwomen. HT effects on BP were negligible. Long-term studies are warranted to assess whether and to what extent HT in trans individuals results in a differential effect on cardiovascular disease outcomes.
Context The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. Design and Methods In this prospective, observational substudy of the European Network for the Investigation of Gender Incongruence, measurements were performed before and after 12 months of HT in 242 transwomen and 188 transmen from 2010 to 2017. Results Mean values are reported. In transmen, HT increased diastolic BP (2.5%; 95% CI, 0.6 to 4.4) and levels of total cholesterol (TC; 4.1%; 95% CI, 1.5 to 6.6), low-density lipoprotein–cholesterol (LDL-C; 13.0%; 95% CI, 9.2 to 16.8), and triglycerides (36.9%; 95% CI, 29.8 to 44.1); high-density lipoprotein–cholesterol levels decreased (HDL-C; 10.8%; 95% CI, −14.0 to −7.6). In transwomen, HT slightly decreased BP (systolic BP, −2.6%, 95% CI, −4.2 to −1.0; diastolic BP, −2.2%, 95% CI, −4.0 to −0.4) and decreased levels of TC (−9.7%; 95% CI, −11.3 to −8.1), LDL-C (−6.0%; 95% CI, −8.6 to 3.6), HDL-C (−9.3%; 95% CI, −11.4 to −7.3), and triglycerides (−10.2%; 95% CI, −14.5 to −5.9). Conclusion Unfavorable changes in lipid profile were observed in transmen; a favorable effect was noted in transwomen. HT effects on BP were negligible. Long-term studies are warranted to assess whether and to what extent HT in trans individuals results in a differential effect on cardiovascular disease outcomes.
Abstract Context The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. Design and Methods In this prospective, observational substudy of the European Network for the Investigation of Gender Incongruence, measurements were performed before and after 12 months of HT in 242 transwomen and 188 transmen from 2010 to 2017. Results Mean values are reported. In transmen, HT increased diastolic BP (2.5%; 95% CI, 0.6 to 4.4) and levels of total cholesterol (TC; 4.1%; 95% CI, 1.5 to 6.6), low-density lipoprotein–cholesterol (LDL-C; 13.0%; 95% CI, 9.2 to 16.8), and triglycerides (36.9%; 95% CI, 29.8 to 44.1); high-density lipoprotein–cholesterol levels decreased (HDL-C; 10.8%; 95% CI, −14.0 to −7.6). In transwomen, HT slightly decreased BP (systolic BP, −2.6%, 95% CI, −4.2 to −1.0; diastolic BP, −2.2%, 95% CI, −4.0 to −0.4) and decreased levels of TC (−9.7%; 95% CI, −11.3 to −8.1), LDL-C (−6.0%; 95% CI, −8.6 to 3.6), HDL-C (−9.3%; 95% CI, −11.4 to −7.3), and triglycerides (−10.2%; 95% CI, −14.5 to −5.9). Conclusion Unfavorable changes in lipid profile were observed in transmen; a favorable effect was noted in transwomen. HT effects on BP were negligible. Long-term studies are warranted to assess whether and to what extent HT in trans individuals results in a differential effect on cardiovascular disease outcomes. In this prospective observational study, favorable lipid changes were found in transwomen and unfavorable lipid changes found in transmen after 12 months of gender-affirming hormone therapy.
Audience Academic
Author Hovingh, G Kees
Simsek, Suat
den Heijer, Martin
Defreyne, Justine
Nota, Nienke M
Thijs, Abel
Klaver, Maartje
van Velzen, Daan M
Paldino, Alessia
T’Sjoen, Guy
AuthorAffiliation Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands Department of Endocrinology, Northwest Clinics, Wilhelminalaan, JD Alkmaar, Netherlands Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata, Via Giovanni Sai, Trieste, Italy University of Trieste, Trieste, Italy Department of Endocrinology, Ghent University Hospital, Corneel Heymanslaan, Ghent, Belgium Center for Sexology and Gender, Ghent University Hospital, Corneel Heymanslaan, Ghent, Belgium Department of Vascular Medicine, Amsterdam University Medical Center, Meibergdreef DD, Amsterdam, Netherlands
AuthorAffiliation_xml – name: Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands Department of Endocrinology, Northwest Clinics, Wilhelminalaan, JD Alkmaar, Netherlands Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata, Via Giovanni Sai, Trieste, Italy University of Trieste, Trieste, Italy Department of Endocrinology, Ghent University Hospital, Corneel Heymanslaan, Ghent, Belgium Center for Sexology and Gender, Ghent University Hospital, Corneel Heymanslaan, Ghent, Belgium Department of Vascular Medicine, Amsterdam University Medical Center, Meibergdreef DD, Amsterdam, Netherlands
Author_xml – sequence: 1
  givenname: Daan M
  orcidid: 0000-0003-1820-3140
  surname: van Velzen
  fullname: van Velzen, Daan M
  organization: Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands
– sequence: 2
  givenname: Alessia
  surname: Paldino
  fullname: Paldino, Alessia
  organization: Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands
– sequence: 3
  givenname: Maartje
  surname: Klaver
  fullname: Klaver, Maartje
  organization: Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands
– sequence: 4
  givenname: Nienke M
  surname: Nota
  fullname: Nota, Nienke M
  organization: Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands
– sequence: 5
  givenname: Justine
  surname: Defreyne
  fullname: Defreyne, Justine
  organization: Department of Endocrinology, Ghent University Hospital, Corneel Heymanslaan, Ghent, Belgium
– sequence: 6
  givenname: G Kees
  surname: Hovingh
  fullname: Hovingh, G Kees
  organization: Department of Vascular Medicine, Amsterdam University Medical Center, Meibergdreef DD, Amsterdam, Netherlands
– sequence: 7
  givenname: Abel
  surname: Thijs
  fullname: Thijs, Abel
  organization: Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands
– sequence: 8
  givenname: Suat
  surname: Simsek
  fullname: Simsek, Suat
  organization: Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands
– sequence: 9
  givenname: Guy
  surname: T’Sjoen
  fullname: T’Sjoen, Guy
  organization: Department of Endocrinology, Ghent University Hospital, Corneel Heymanslaan, Ghent, Belgium
– sequence: 10
  givenname: Martin
  surname: den Heijer
  fullname: den Heijer, Martin
  email: m.denheijer@vumc.nl
  organization: Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30602016$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1rGzEQxUVJaJy0x17LQi-5rKuPXWl1NMZNCoH24EBvQpZGzrq7kivtYvLfV443DQ0tOggNv3nzNO8SnfngAaEPBM8JJfjzzswpJk2JKWHNGzQjsqpLQaQ4QzOci6UU9McFukxphzGpqpq9RRcMc5y7-AxtlzraNvQw6E3oWlOsnAMzpCK4Yg1pCGmAmCcWrS_WUfvUgy-0t8UqDTFs8-N7N6Zi-biPYSIXJosNLx2HrO7foXOnuwTvp_sK3X9ZrZe35d23m6_LxV1pat40JaFVhYmDSnKnBRYYpKOO0Y3AxEpKBK8q4Ryra00lt0BAOGEZYZxayxrLrtD1STf7-TXmD6i-TQa6TnsIY1KUcIZJXgzP6KdX6C6M0Wd3ijJeUSapbF6ore5Atd6FIWpzFFWL7LjmopYyU_N_UPlY6FuTt-LaXP-roTw1mBhSiuDUPra9jo-KYHUMVu2MOgarnoLN_MfJ7Ljpwf6hn5PMADkBh9DlINLPbjxAVA-gu-HhtWj5LDotK4z7_82f0N-z3rlh
CitedBy_id crossref_primary_10_1016_j_jcte_2024_100349
crossref_primary_10_1016_j_eprac_2020_11_001
crossref_primary_10_1097_HJH_0000000000002632
crossref_primary_10_1016_j_jacl_2022_11_010
crossref_primary_10_1016_j_metop_2022_100173
crossref_primary_10_1089_trgh_2021_0023
crossref_primary_10_1177_20420188231166494
crossref_primary_10_1016_j_atherosclerosis_2023_117277
crossref_primary_10_1210_clinem_dgab515
crossref_primary_10_1016_j_atherosclerosis_2021_03_008
crossref_primary_10_1080_14737175_2023_2296610
crossref_primary_10_1186_s40360_023_00724_4
crossref_primary_10_1161_HYPERTENSIONAHA_120_16839
crossref_primary_10_1080_17446651_2020_1825075
crossref_primary_10_1210_clinem_dgae226
crossref_primary_10_1093_ejendo_lvad170
crossref_primary_10_2139_ssrn_3915417
crossref_primary_10_1016_S2213_8587_21_00185_6
crossref_primary_10_1080_13697137_2024_2310518
crossref_primary_10_3390_children6050063
crossref_primary_10_1016_j_ajpc_2021_100223
crossref_primary_10_1097_JCMA_0000000000000475
crossref_primary_10_1016_j_clnesp_2020_08_011
crossref_primary_10_1016_j_cct_2023_107243
crossref_primary_10_1016_S2213_8587_21_00211_4
crossref_primary_10_1016_j_maturitas_2019_08_010
crossref_primary_10_1210_clinem_dgab427
crossref_primary_10_1161_CIR_0000000000001003
crossref_primary_10_1016_j_advnut_2023_07_009
crossref_primary_10_1038_s41443_020_0323_8
crossref_primary_10_1177_20533691231198635
crossref_primary_10_1016_j_beem_2024_101907
crossref_primary_10_1007_s00125_024_06212_6
crossref_primary_10_1038_s41366_021_00935_x
crossref_primary_10_1016_j_otc_2022_04_002
crossref_primary_10_3390_jcm12196141
crossref_primary_10_7759_cureus_58137
crossref_primary_10_1152_ajpheart_00015_2023
crossref_primary_10_1007_s40618_021_01694_2
crossref_primary_10_1253_circrep_CR_23_0021
crossref_primary_10_1210_clinem_dgab934
crossref_primary_10_3390_jcm11071784
crossref_primary_10_1111_joim_13441
crossref_primary_10_1210_clinem_dgab616
crossref_primary_10_1161_HYPERTENSIONAHA_119_13080
crossref_primary_10_1016_j_jsxm_2021_01_185
crossref_primary_10_3389_fnut_2024_1339311
crossref_primary_10_1007_s11904_021_00572_z
crossref_primary_10_3390_endocrines3020026
crossref_primary_10_1016_j_echo_2024_05_004
crossref_primary_10_1371_journal_pone_0261312
crossref_primary_10_1007_s11606_021_06634_7
crossref_primary_10_1016_j_fertnstert_2021_07_1206
crossref_primary_10_1530_EC_22_0112
crossref_primary_10_2215_CJN_0000000000000289
crossref_primary_10_1007_s11883_022_01047_1
crossref_primary_10_1007_s41969_019_00080_x
crossref_primary_10_1016_j_jcte_2020_100230
crossref_primary_10_1038_s41371_022_00721_w
crossref_primary_10_1186_s12944_024_02131_y
crossref_primary_10_3390_ijms23084300
crossref_primary_10_1016_j_bja_2020_01_024
crossref_primary_10_2215_CJN_01890222
crossref_primary_10_1038_s41440_022_01067_z
crossref_primary_10_1001_jamanetworkopen_2024_19696
crossref_primary_10_1038_s41440_022_01162_1
crossref_primary_10_1186_s13293_024_00586_3
Cites_doi 10.1210/jc.2013-3399
10.7326/M17-2785
10.1172/JCI116588
10.1371/journal.pone.0085805
10.1111/j.1365-2265.1986.tb00761.x
10.1111/j.1742-1241.2008.01877.x
10.1161/ATVBAHA.111.241885
10.1001/jama.280.7.605
10.1161/01.ATV.20.5.1396
10.1016/j.jpsychores.2015.02.001
10.1016/0026-0495(89)90233-3
10.1530/eje.1.02166
10.1007/s11154-018-9454-3
10.1111/j.1743-6109.2011.02311.x
10.1161/01.ATV.0000199248.53590.e1
10.1111/andr.12382
10.1111/cen.13372
10.1530/EJE-17-0124
10.1016/j.eurpsy.2010.04.009
10.1016/j.molmet.2018.04.003
10.1530/EJE-17-0496
10.1210/endo.138.9.5404
10.1016/j.jsxm.2016.09.012
10.1056/NEJM199110243251702
10.1001/jama.291.14.1701
10.1530/EJE-10-1038
10.1677/joe.1.07070
10.1007/s40618-016-0480-2
10.1123/jpah.2017-0298
10.1001/jama.1995.03520270033028
10.1001/jama.1983.03330310033022
10.1016/j.jsxm.2016.03.371
10.1210/jc.2017-01643
10.1161/ATVBAHA.115.305460
10.1016/0026-0495(83)90052-5
10.1016/S0006-291X(02)02038-7
10.1056/NEJMoa1505241
10.1046/j.1365-2265.2003.01753.x
10.1111/andr.12485
10.1056/NEJM199608153350701
10.1001/jama.2016.21043
10.1016/S0015-0282(01)01699-5
10.3389/fendo.2014.00241
10.1016/S0033-0620(95)80016-6
10.1111/j.1467-789X.2009.00623.x
10.1161/01.CIR.102.16.1906
10.1161/01.ATV.0000172629.12846.b8
10.1111/andr.12425
10.1001/jama.288.3.321
10.1016/j.jacc.2016.06.067
10.1210/jc.2017-01658
10.1111/cen.13050
10.1111/j.1365-2265.2011.04015.x
10.1093/eurheartj/ehx628
ContentType Journal Article
Copyright Copyright © 2019 Endocrine Society 2019
Copyright © Oxford University Press 2015
Copyright © 2019 Endocrine Society.
COPYRIGHT 2019 Oxford University Press
Copyright © 2019 Endocrine Society
Copyright_xml – notice: Copyright © 2019 Endocrine Society 2019
– notice: Copyright © Oxford University Press 2015
– notice: Copyright © 2019 Endocrine Society.
– notice: COPYRIGHT 2019 Oxford University Press
– notice: Copyright © 2019 Endocrine Society
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7QP
7T5
7TM
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
M0S
M1P
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1210/jc.2018-02138
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest One Academic Eastern Edition
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
AIDS and Cancer Research Abstracts
Immunology Abstracts
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
ProQuest One Academic Eastern Edition
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X7
  name: Health Medical collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage 1947
ExternalDocumentID A688567599
10_1210_jc_2018_02138
30602016
10.1210/jc.2018-02138
Genre Journal Article
Observational Study
GeographicLocations Belgium
Netherlands
GeographicLocations_xml – name: Netherlands
– name: Belgium
GroupedDBID ---
-~X
.55
.GJ
.XZ
08P
0R~
18M
1TH
29K
2WC
34G
354
39C
3O-
3V.
4.4
48X
53G
5GY
5RS
5YH
8F7
AABZA
AACZT
AAIMJ
AAJQQ
AAKAS
AAPGJ
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
AAYJJ
ABBLC
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPMR
ABPPZ
ABPQP
ABPTD
ABQNK
ABSAR
ABWST
ABXVV
ACFRR
ACGFO
ACGFS
ACPRK
ACUTJ
ACYHN
ACZBC
ADBBV
ADGKP
ADGZP
ADHKW
ADQBN
ADRTK
ADVEK
ADZCM
AELWJ
AEMDU
AENEX
AENZO
AERZD
AETBJ
AEWNT
AFCHL
AFFNX
AFFZL
AFGWE
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGKRT
AGMDO
AGQXC
AGUTN
AHMBA
AI.
AJEEA
ALMA_UNASSIGNED_HOLDINGS
APIBT
APJGH
AQDSO
AQKUS
ARIXL
ASPBG
ATGXG
AVNTJ
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BENPR
BEYMZ
BPHCQ
BSWAC
BTRTY
BVXVI
C45
CDBKE
CS3
D-I
DAKXR
DIK
E3Z
EBS
EIHJH
EJD
EMOBN
ENERS
F5P
FECEO
FEDTE
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
G8K
GAUVT
GJXCC
GX1
H13
HVGLF
HZ~
H~9
IAO
IHR
INH
J5H
KBUDW
KOP
KQ8
KSI
KSN
L7B
M5~
MBLQV
MHKGH
MJL
N4W
N9A
NLBLG
NOMLY
NOYVH
NVLIB
O9-
OAUYM
OBH
OCB
ODMLO
OFXIZ
OGEVE
OHH
OJZSN
OK1
OPAEJ
OVD
OVIDX
P2P
P6G
PQQKQ
PROAC
REU
ROX
ROZ
TEORI
TJX
TLC
TMA
TR2
TWZ
VH1
VVN
W8F
WHG
WOQ
X52
X7M
YBU
YFH
YHG
YOC
YSK
ZGI
ZXP
ZY1
~02
~H1
-
02
08R
0R
3RD
55
7X7
88E
8FI
8FJ
AABJS
AABMN
ABFLS
ABUWG
ACIMA
ADEIU
AELNO
AFKRA
AFXEN
AGVJH
AIKOY
AIMBJ
AJYGW
ASMCH
AYOIW
AZQFJ
BBAFP
BGYMP
BHONS
DPPUQ
FH7
FYUFA
GJ
H1
HZ
M1P
M2M
M5
O0-
PQEST
PQUKI
PRINS
PSQYO
ROL
TCN
X
XZ
ZA5
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
CITATION
ABXZS
ALXQX
BYORX
CASEJ
7QP
7T5
7TM
7XB
8FK
CCPQU
H94
K9.
7X8
ID FETCH-LOGICAL-c5688-124401fe496fa7070e9f2f32b701d92176447ff355a296de1e7f7d31362dd38d3
IEDL.DBID 7X7
ISSN 0021-972X
IngestDate Sat Oct 26 00:33:48 EDT 2024
Thu Oct 10 20:47:05 EDT 2024
Thu Feb 22 23:47:42 EST 2024
Mon Jan 01 07:17:11 EST 2024
Thu Sep 26 15:40:28 EDT 2024
Sat Sep 28 08:27:54 EDT 2024
Thu Aug 13 19:51:48 EDT 2020
Wed Aug 28 03:19:30 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Copyright © 2019 Endocrine Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5688-124401fe496fa7070e9f2f32b701d92176447ff355a296de1e7f7d31362dd38d3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ORCID 0000-0003-1820-3140
OpenAccessLink https://academic.oup.com/jcem/article-pdf/104/6/1937/28462647/jc.2018-02138.pdf
PMID 30602016
PQID 2364239298
PQPubID 2046206
PageCount 11
ParticipantIDs proquest_miscellaneous_2163010026
proquest_journals_2364239298
gale_infotracmisc_A688567599
gale_infotracacademiconefile_A688567599
crossref_primary_10_1210_jc_2018_02138
pubmed_primary_30602016
wolterskluwer_health_10_1210_jc_2018-02138
oup_primary_10_1210_jc_2018-02138
ProviderPackageCode .XZ
OBH
C45
5RS
AFCHL
OGEVE
~H1
ABPMR
M5~
OVD
OCB
PublicationCentury 2000
PublicationDate 2019-June
PublicationDateYYYYMMDD 2019-06-01
PublicationDate_xml – month: 06
  year: 2019
  text: 2019-June
PublicationDecade 2010
PublicationPlace Washington, DC
PublicationPlace_xml – name: Washington, DC
– name: United States
– name: Washington
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2019
Publisher Endocrine Society
Copyright Oxford University Press
Oxford University Press
Publisher_xml – name: Endocrine Society
– name: Copyright Oxford University Press
– name: Oxford University Press
References (2019041614024645100_B4) 1995; 273
Defreyne (2019041614024645100_B41) 2018; 6
Elbers (2019041614024645100_B14) 2003; 58
Langer (2019041614024645100_B32) 2002; 296
Asscheman (2019041614024645100_B55) 2011; 164
Polderman (2019041614024645100_B29) 1994; 79
Grodstein (2019041614024645100_B2) 1996; 335
Maraka (2019041614024645100_B11) 2017; 102
Soares (2019041614024645100_B47) 2009; 63
Gava (2019041614024645100_B51) 2016; 85
Schiffer (2019041614024645100_B40) 2017; 177
Finkle (2019041614024645100_B9) 2014; 9
O’Reilly (2019041614024645100_B27) 2014; 99
Corbould (2019041614024645100_B28) 2007; 192
Colizzi (2019041614024645100_B12) 2015; 78
Lamon-Fava (2019041614024645100_B48) 2006; 26
Getahun (2019041614024645100_B57) 2018; 169
Timmis (2019041614024645100_B1) 2018; 39
Hembree (2019041614024645100_B18) 2017; 102
Zhang (2019041614024645100_B8) 2018; 6
Croston (2019041614024645100_B34) 1997; 138
Haffner (2019041614024645100_B33) 1983; 32
Wynn (2019041614024645100_B52) 1986; 24
Kapoor (2019041614024645100_B25) 2006; 154
Wolfe (2019041614024645100_B49) 1993; 92
Dekker (2019041614024645100_B16) 2016; 13
Bush (2019041614024645100_B3) 1983; 249
2019041614024645100_B19
Asscheman (2019041614024645100_B56) 1989; 38
Jones (2019041614024645100_B53) 2018; 15
Irwig (2019041614024645100_B20) 2018; 19
Rasmussen (2019041614024645100_B26) 2017; 87
Varlamov (2019041614024645100_B31) 2015; 5
Klaver (2019041614024645100_B35) 2018; 178
Velho (2019041614024645100_B15) 2017; 5
Matthan (2019041614024645100_B45) 2005; 25
English (2019041614024645100_B7) 2000; 102
Ott (2019041614024645100_B21) 2011; 8
Hodis (2019041614024645100_B43) 2016; 374
Giltay (2019041614024645100_B13) 2000; 20
Kreukels (2019041614024645100_B17) 2012; 27
Rossouw (2019041614024645100_B5) 2002; 288
Corona (2019041614024645100_B22) 2016; 39
Ibrahim (2019041614024645100_B36) 2010; 11
Hulley (2019041614024645100_B42) 1998; 280
Fung (2019041614024645100_B50) 2016; 13
Jones (2019041614024645100_B54)
Bagatell (2019041614024645100_B23) 1995; 38
Zore (2019041614024645100_B38) 2018; 15
Lee (2019041614024645100_B37) 2016; 68
Walsh (2019041614024645100_B44) 1991; 325
Sidhwani (2019041614024645100_B24) 2011; 75
Anderson (2019041614024645100_B6) 2004; 291
Budoff (2019041614024645100_B10) 2017; 317
Reaven (2019041614024645100_B30) 2012; 32
Link (2019041614024645100_B39) 2015; 35
Godsland (2019041614024645100_B46) 2001; 75
References_xml – volume: 99
  start-page: 1027
  issue: 3
  year: 2014
  ident: 2019041614024645100_B27
  article-title: Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2013-3399
  contributor:
    fullname: O’Reilly
– volume: 169
  start-page: 205
  issue: 4
  year: 2018
  ident: 2019041614024645100_B57
  article-title: Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study
  publication-title: Ann Intern Med
  doi: 10.7326/M17-2785
  contributor:
    fullname: Getahun
– volume: 92
  start-page: 456
  issue: 1
  year: 1993
  ident: 2019041614024645100_B49
  article-title: Effects of low dosage progestin-only administration upon plasma triglycerides and lipoprotein metabolism in postmenopausal women
  publication-title: J Clin Invest
  doi: 10.1172/JCI116588
  contributor:
    fullname: Wolfe
– volume: 9
  start-page: e85805
  issue: 1
  year: 2014
  ident: 2019041614024645100_B9
  article-title: Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0085805
  contributor:
    fullname: Finkle
– volume: 24
  start-page: 183
  issue: 2
  year: 1986
  ident: 2019041614024645100_B52
  article-title: Paradoxical effects of the anti-androgen cyproterone acetate on lipid and lipoprotein metabolism
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.1986.tb00761.x
  contributor:
    fullname: Wynn
– volume: 63
  start-page: 160
  issue: 1
  year: 2009
  ident: 2019041614024645100_B47
  article-title: Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome
  publication-title: Int J Clin Pract
  doi: 10.1111/j.1742-1241.2008.01877.x
  contributor:
    fullname: Soares
– volume: 32
  start-page: 1754
  issue: 8
  year: 2012
  ident: 2019041614024645100_B30
  article-title: Insulin resistance and coronary heart disease in nondiabetic individuals
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.111.241885
  contributor:
    fullname: Reaven
– volume: 280
  start-page: 605
  issue: 7
  year: 1998
  ident: 2019041614024645100_B42
  article-title: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
  publication-title: JAMA
  doi: 10.1001/jama.280.7.605
  contributor:
    fullname: Hulley
– volume: 20
  start-page: 1396
  issue: 5
  year: 2000
  ident: 2019041614024645100_B13
  article-title: Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.20.5.1396
  contributor:
    fullname: Giltay
– volume: 78
  start-page: 399
  issue: 4
  year: 2015
  ident: 2019041614024645100_B12
  article-title: Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study
  publication-title: J Psychosom Res
  doi: 10.1016/j.jpsychores.2015.02.001
  contributor:
    fullname: Colizzi
– volume: 38
  start-page: 869
  issue: 9
  year: 1989
  ident: 2019041614024645100_B56
  article-title: Mortality and morbidity in transsexual patients with cross-gender hormone treatment
  publication-title: Metabolism
  doi: 10.1016/0026-0495(89)90233-3
  contributor:
    fullname: Asscheman
– volume: 154
  start-page: 899
  issue: 6
  year: 2006
  ident: 2019041614024645100_B25
  article-title: Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes
  publication-title: Eur J Endocrinol
  doi: 10.1530/eje.1.02166
  contributor:
    fullname: Kapoor
– volume: 19
  start-page: 243
  issue: 3
  year: 2018
  ident: 2019041614024645100_B20
  article-title: Cardiovascular health in transgender people
  publication-title: Rev Endocr Metab Disord
  doi: 10.1007/s11154-018-9454-3
  contributor:
    fullname: Irwig
– volume: 8
  start-page: 2361
  issue: 8
  year: 2011
  ident: 2019041614024645100_B21
  article-title: Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals
  publication-title: J Sex Med
  doi: 10.1111/j.1743-6109.2011.02311.x
  contributor:
    fullname: Ott
– volume: 26
  start-page: 385
  issue: 2
  year: 2006
  ident: 2019041614024645100_B48
  article-title: Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000199248.53590.e1
  contributor:
    fullname: Lamon-Fava
– volume: 5
  start-page: 881
  issue: 5
  year: 2017
  ident: 2019041614024645100_B15
  article-title: Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review
  publication-title: Andrology
  doi: 10.1111/andr.12382
  contributor:
    fullname: Velho
– volume: 87
  start-page: 249
  issue: 3
  year: 2017
  ident: 2019041614024645100_B26
  article-title: Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/cen.13372
  contributor:
    fullname: Rasmussen
– volume: 79
  start-page: 265
  issue: 1
  year: 1994
  ident: 2019041614024645100_B29
  article-title: Induction of insulin resistance by androgens and estrogens
  publication-title: J Clin Endocrinol Metab
  contributor:
    fullname: Polderman
– volume: 177
  start-page: R125
  issue: 3
  year: 2017
  ident: 2019041614024645100_B40
  article-title: Mechanisms in endocrinology: the sexually dimorphic role of androgens in human metabolic disease
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-17-0124
  contributor:
    fullname: Schiffer
– volume: 27
  start-page: 445
  issue: 6
  year: 2012
  ident: 2019041614024645100_B17
  article-title: A European network for the investigation of gender incongruence: the ENIGI initiative
  publication-title: Eur Psychiatry
  doi: 10.1016/j.eurpsy.2010.04.009
  contributor:
    fullname: Kreukels
– volume: 15
  start-page: 35
  year: 2018
  ident: 2019041614024645100_B38
  article-title: Sex differences in obesity, lipid metabolism, and inflammation-a role for the sex chromosomes
  publication-title: Mol Metab
  doi: 10.1016/j.molmet.2018.04.003
  contributor:
    fullname: Zore
– volume: 178
  start-page: 165
  issue: 2
  year: 2018
  ident: 2019041614024645100_B35
  article-title: Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-17-0496
  contributor:
    fullname: Klaver
– volume: 138
  start-page: 3779
  issue: 9
  year: 1997
  ident: 2019041614024645100_B34
  article-title: Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes
  publication-title: Endocrinology
  doi: 10.1210/endo.138.9.5404
  contributor:
    fullname: Croston
– volume: 13
  start-page: 1765
  issue: 11
  year: 2016
  ident: 2019041614024645100_B50
  article-title: Differential effects of cyproterone acetate vs spironolactone on serum high-density lipoprotein and prolactin concentrations in the hormonal treatment of transgender women
  publication-title: J Sex Med
  doi: 10.1016/j.jsxm.2016.09.012
  contributor:
    fullname: Fung
– volume: 325
  start-page: 1196
  issue: 17
  year: 1991
  ident: 2019041614024645100_B44
  article-title: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199110243251702
  contributor:
    fullname: Walsh
– volume: 291
  start-page: 1701
  issue: 14
  year: 2004
  ident: 2019041614024645100_B6
  article-title: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial
  publication-title: JAMA
  doi: 10.1001/jama.291.14.1701
  contributor:
    fullname: Anderson
– volume: 164
  start-page: 635
  issue: 4
  year: 2011
  ident: 2019041614024645100_B55
  article-title: A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-10-1038
  contributor:
    fullname: Asscheman
– volume: 192
  start-page: 585
  issue: 3
  year: 2007
  ident: 2019041614024645100_B28
  article-title: Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women
  publication-title: J Endocrinol
  doi: 10.1677/joe.1.07070
  contributor:
    fullname: Corbould
– volume: 39
  start-page: 967
  issue: 9
  year: 2016
  ident: 2019041614024645100_B22
  article-title: Testosterone supplementation and body composition: results from a meta-analysis of observational studies
  publication-title: J Endocrinol Invest
  doi: 10.1007/s40618-016-0480-2
  contributor:
    fullname: Corona
– volume: 15
  start-page: 99
  issue: 2
  year: 2018
  ident: 2019041614024645100_B53
  article-title: The levels and predictors of physical activity engagement within the treatment-seeking transgender population: a matched control study
  publication-title: J Phys Act Health
  doi: 10.1123/jpah.2017-0298
  contributor:
    fullname: Jones
– volume: 273
  start-page: 199
  issue: 3
  year: 1995
  ident: 2019041614024645100_B4
  article-title: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
  publication-title: JAMA
  doi: 10.1001/jama.1995.03520270033028
– volume: 249
  start-page: 903
  issue: 7
  year: 1983
  ident: 2019041614024645100_B3
  article-title: Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study
  publication-title: JAMA
  doi: 10.1001/jama.1983.03330310033022
  contributor:
    fullname: Bush
– volume: 13
  start-page: 994
  issue: 6
  year: 2016
  ident: 2019041614024645100_B16
  article-title: A European Network for the Investigation of Gender Incongruence: endocrine part
  publication-title: J Sex Med
  doi: 10.1016/j.jsxm.2016.03.371
  contributor:
    fullname: Dekker
– volume: 102
  start-page: 3914
  issue: 11
  year: 2017
  ident: 2019041614024645100_B11
  article-title: Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2017-01643
  contributor:
    fullname: Maraka
– volume: 35
  start-page: 1778
  issue: 8
  year: 2015
  ident: 2019041614024645100_B39
  article-title: Increased high-density lipoprotein cholesterol levels in mice with XX versus XY sex chromosomes
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.115.305460
  contributor:
    fullname: Link
– volume: 32
  start-page: 413
  issue: 4
  year: 1983
  ident: 2019041614024645100_B33
  article-title: Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy
  publication-title: Metabolism
  doi: 10.1016/0026-0495(83)90052-5
  contributor:
    fullname: Haffner
– volume: 296
  start-page: 1051
  issue: 5
  year: 2002
  ident: 2019041614024645100_B32
  article-title: Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/S0006-291X(02)02038-7
  contributor:
    fullname: Langer
– ident: 2019041614024645100_B54
  contributor:
    fullname: Jones
– volume: 374
  start-page: 1221
  issue: 13
  year: 2016
  ident: 2019041614024645100_B43
  article-title: Vascular effects of early versus late postmenopausal treatment with estradiol
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1505241
  contributor:
    fullname: Hodis
– volume: 58
  start-page: 562
  issue: 5
  year: 2003
  ident: 2019041614024645100_B14
  article-title: Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1046/j.1365-2265.2003.01753.x
  contributor:
    fullname: Elbers
– volume: 6
  start-page: 446
  issue: 3
  year: 2018
  ident: 2019041614024645100_B41
  article-title: Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence
  publication-title: Andrology
  doi: 10.1111/andr.12485
  contributor:
    fullname: Defreyne
– volume: 335
  start-page: 453
  issue: 7
  year: 1996
  ident: 2019041614024645100_B2
  article-title: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199608153350701
  contributor:
    fullname: Grodstein
– volume: 317
  start-page: 708
  issue: 7
  year: 2017
  ident: 2019041614024645100_B10
  article-title: Testosterone treatment and coronary artery plaque volume in older men with low testosterone
  publication-title: JAMA
  doi: 10.1001/jama.2016.21043
  contributor:
    fullname: Budoff
– volume: 75
  start-page: 898
  issue: 5
  year: 2001
  ident: 2019041614024645100_B46
  article-title: Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000
  publication-title: Fertil Steril
  doi: 10.1016/S0015-0282(01)01699-5
  contributor:
    fullname: Godsland
– ident: 2019041614024645100_B19
– volume: 5
  start-page: 241
  year: 2015
  ident: 2019041614024645100_B31
  article-title: Sex-specific differences in lipid and glucose metabolism
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2014.00241
  contributor:
    fullname: Varlamov
– volume: 38
  start-page: 255
  issue: 3
  year: 1995
  ident: 2019041614024645100_B23
  article-title: Androgen and progestagen effects on plasma lipids
  publication-title: Prog Cardiovasc Dis
  doi: 10.1016/S0033-0620(95)80016-6
  contributor:
    fullname: Bagatell
– volume: 11
  start-page: 11
  issue: 1
  year: 2010
  ident: 2019041614024645100_B36
  article-title: Subcutaneous and visceral adipose tissue: structural and functional differences
  publication-title: Obes Rev
  doi: 10.1111/j.1467-789X.2009.00623.x
  contributor:
    fullname: Ibrahim
– volume: 102
  start-page: 1906
  issue: 16
  year: 2000
  ident: 2019041614024645100_B7
  article-title: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study
  publication-title: Circulation
  doi: 10.1161/01.CIR.102.16.1906
  contributor:
    fullname: English
– volume: 25
  start-page: 1691
  issue: 8
  year: 2005
  ident: 2019041614024645100_B45
  article-title: TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000172629.12846.b8
  contributor:
    fullname: Matthan
– volume: 6
  start-page: 37
  issue: 1
  year: 2018
  ident: 2019041614024645100_B8
  article-title: Effects of testosterone supplementation therapy on lipid metabolism in hypogonadal men with T2DM: a meta-analysis of randomized controlled trials
  publication-title: Andrology
  doi: 10.1111/andr.12425
  contributor:
    fullname: Zhang
– volume: 288
  start-page: 321
  issue: 3
  year: 2002
  ident: 2019041614024645100_B5
  article-title: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial
  publication-title: JAMA
  doi: 10.1001/jama.288.3.321
  contributor:
    fullname: Rossouw
– volume: 68
  start-page: 1509
  issue: 14
  year: 2016
  ident: 2019041614024645100_B37
  article-title: Association of changes in abdominal fat quantity and quality with incident cardiovascular disease risk factors
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2016.06.067
  contributor:
    fullname: Lee
– volume: 102
  start-page: 3869
  issue: 11
  year: 2017
  ident: 2019041614024645100_B18
  article-title: Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2017-01658
  contributor:
    fullname: Hembree
– volume: 85
  start-page: 239
  issue: 2
  year: 2016
  ident: 2019041614024645100_B51
  article-title: Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/cen.13050
  contributor:
    fullname: Gava
– volume: 75
  start-page: 76
  issue: 1
  year: 2011
  ident: 2019041614024645100_B24
  article-title: Polycystic ovary syndrome is associated with atherogenic changes in lipoprotein particle number and size independent of body weight
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.2011.04015.x
  contributor:
    fullname: Sidhwani
– volume: 39
  start-page: 508
  issue: 7
  year: 2018
  ident: 2019041614024645100_B1
  article-title: European Society of Cardiology: cardiovascular disease statistics 2017
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehx628
  contributor:
    fullname: Timmis
SSID ssj0014453
Score 2.5768454
Snippet Abstract Context The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective The effects of 1 year of...
The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. The effects of 1 year of treatment with oral or...
Context: The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective: The effects of 1 year of treatment...
Context The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. Objective The effects of 1 year of treatment with...
CONTEXTThe impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. OBJECTIVEThe effects of 1 year of treatment with...
SourceID proquest
gale
crossref
pubmed
wolterskluwer
oup
SourceType Aggregation Database
Index Database
Publisher
StartPage 1937
SubjectTerms Acetates
Acetic acid
Administration, Oral
Adolescent
Adult
Blood pressure
Blood Pressure - drug effects
Cardiovascular diseases
Cardiovascular Diseases - blood
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - prevention & control
Cholesterol
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Cyproterone acetate
Cyproterone Acetate - administration & dosage
Cyproterone Acetate - adverse effects
Estrogen
Estrogens
Estrogens - administration & dosage
Estrogens - adverse effects
Female
High density lipoprotein
Hormone Replacement Therapy - adverse effects
Hormone Replacement Therapy - methods
Hormones
Humans
Low density lipoprotein
Low density lipoproteins
Male
Phenols
Prospective Studies
Sex Factors
Sex Reassignment Procedures - adverse effects
Sex Reassignment Procedures - methods
Testosterone
Testosterone - administration & dosage
Testosterone - adverse effects
Transdermal medication
Transdermal Patch
Transgender people
Transgender Persons
Triglycerides
Triglycerides - blood
Young Adult
Title Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen
URI https://www.ncbi.nlm.nih.gov/pubmed/30602016
https://www.proquest.com/docview/2364239298
https://search.proquest.com/docview/2163010026
Volume 104
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3raxQxEB-0BbGI-Pb0LBFEQVjc7CObfJLzuFKEliIt3Lewu0lKa7vb3u4h_vfOZHPXO1A_J5sJ88jMbGZ-AfggLDeiUkUkJIFq89pFZYWBXCbSTFqVqTilRuGjY3F4ln2f5_Pww60LZZWrM9Ef1Kat6R_5FwI6T8iZy683txG9GkW3q-EJjfuwy5NYUElXMV8nXJgrBBRKKkMoknnA2KSulUuCL-QywiFqTdnwSeFk3mp324g69-DRr5Yusrufvo59wxsdPIHHIYxkk0HuT-GebZ7Bg6NwUf4czqe-zvTa9ijkq4uaDSjFHWsdO6XHZAgfoW0su2iYd1fXtmFlY9is6xctKhU7uVp2bPrb4zj4mZOaKhPvvvDYDS_g7GB2Oj2MwpsKUZ0LNApy5zF3NlPClQXau1UucWlSFTE3CvMTjI8K5zAKKRMljOW2cIVJOfo5Y1Jp0pew0yDR18CSKpdUyWlyabJSuhJjL-nwCFBlUtk8H8HHFVf1zQCdoSnlQPbry1oT-7Vn_wg-Ec81mVS_KOsydAYgGQKn0hPceI6JjVIjGG_NRFOot4bfo9T-RSwKxMYrmepgrp2-Uy5cYj1Mq1MJWmPbJc7ByDUmwFoxgleDLqwpYd6FYTfHkc9byqGHZta_7-TN_3fyFh7iXDWUpY1hp18s7TsMgPpq32v5Pux-mx2f_PgDIt__uQ
link.rule.ids 315,783,787,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3rixMxEB_0DvRExNdptWoEURAWu69s8klq6VH1Wg7pQb-F7CaRO-92z-4W8b93ZjfttaB-zmPCZCYzk8z8AvCG29DwXGYBFwSqHRYu0Dk6cgmPE2FlIgcxFQpPZ3xymnxZpAt_4Vb7tMr1mdge1KYq6I78AwGdR2TMxcernwH9GkWvq_4LjZuwT1BVGHztfxrPTr5t3hGSxONQUiJCFi08yibVrZwTgGEoAmyi4pQtq-TP5p2Cty2_8w7c_VXRU3b9o81k37JHR_fhnnck2bDb-Qdww5YP4dbUP5U_gu-jNtP00ja4zRdnBetwimtWOTan72QIIaEqLTsrWWuwLm3JdGnYuG6WFYoVO7lY1Wz0u0VyaHsOC8pNvB7Rojc8htOj8Xw0CfyvCkGRclQLMuiD0NlEcqcz1HgrXeTiKM8GoZEYoaCHlDmHfoiOJDc2tJnLTByipTMmFiY-hL0SiT4FFuWpoFxOkwqTaOE0el_C4SEgdZTbNO3B2zVX1VUHnqEo6ED2q_NCEftVy_4evCOeK1KqZqkL7WsDkAzBU6khLjzF0EbKHvR3eqIyFDvNr3HX_kUs8MT66z1VXmFrdS1eOMWmmWanJLTSVivsg77rgCBreQ-edLKwoYSRFzreIba83xEO1ZWz_n0lz_6_kldwezKfHqvjz7Ovz-EAx8kuSa0Pe81yZV-gO9TkL73M_wGn9QKE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiometabolic+Effects+of+Testosterone+in+Transmen+and+Estrogen+Plus+Cyproterone+Acetate+in+Transwomen&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=van+Velzen%2C+Daan+M&rft.au=Paldino%2C+Alessia&rft.au=Klaver%2C+Maartje&rft.au=Nota%2C+Nienke+M&rft.date=2019-06-01&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=104&rft.issue=6&rft.spage=1937&rft.epage=1947&rft_id=info:doi/10.1210%2Fjc.2018-02138&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_jc_2018_02138
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon